Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Short Communication - Journal of Cancer Immunology & Therapy (2024) Volume 7, Issue 5

Tumor microenvironment: The role of immune cells in cancer progression.

Grady Ozalp *

Department of Dermatology, University Hospital Carl Gustav Carus, Germany

*Corresponding Author:
Grady Ozalp
Department of Dermatology, University Hospital Carl Gustav Carus, Germany
E-mail: ozalp.gr@gmail.com

Received: 27-Sep -2024, Manuscript No. AAJCIT-24-150275; Editor assigned: 28-Sep-2024, PreQC No. AAJCIT-24-150275 (PQ); Reviewed:14-Oct-2024, QC No. AAJCIT-24-150275; Revised:19-Oct-2024, Manuscript No. AAJCIT-24-150275 (R); Published:28-Oct-2024, DOI:10.35841/aara-7.5.235

Citation: Ozalp G., Tumor microenvironment: The role of immune cells in cancer progression. J Cancer Immunol Ther. 2024;7(5):235

Visit for more related articles at Journal of Cancer Immunology & Therapy

Introduction

The tumor microenvironment (TME) is a complex and dynamic ecosystem that comprises various cell types, extracellular matrix components, and signaling molecules. Immune cells play a pivotal role in the TME, influencing tumor growth, progression, and metastasis. The interplay between tumor cells and immune cells can be both beneficial and detrimental, depending on the context and the types of immune cells involved. This article explores the role of immune cells in the TME, highlighting their contributions to cancer progression and potential therapeutic implications [1].

The TME consists of a diverse array of cells, including tumor cells, immune cells, fibroblasts, endothelial cells, and mesenchymal stem cells. Among these, immune cells are crucial players that can either promote or inhibit tumor growth. Key immune cell types found in the TME include: These include cytotoxic T cells (CD8+) and helper T cells (CD4+), which can exert anti-tumor effects through the recognition and elimination of malignant cells [2].

Combining immune checkpoint inhibitors with other modalities, such as chemotherapy or targeted therapies, may enhance treatment efficacy by simultaneously targeting different aspects of the TME. Such strategies could help overcome resistance mechanisms and improve patient outcomes. Tregs are instrumental in maintaining immune tolerance and can suppress the activity of effector T cells, thereby facilitating tumor progression. These cells are often recruited to the TME and can inhibit T cell activation and promote tumor growth through various mechanisms [3].

Tumor-associated macrophages (TAMs) can adopt different phenotypes, with M1 macrophages generally exhibiting anti-tumor properties and M2 macrophages promoting tumor growth and metastasis.These antigen-presenting cells are essential for initiating immune responses. However, in the TME, their function can be impaired, leading to suboptimal activation of T cells [4].

Cancer cells have developed sophisticated mechanisms to evade the immune response. One significant strategy is the recruitment and activation of immunosuppressive cells, such as Tregs and MDSCs. Tregs can inhibit the activity of cytotoxic T cells, leading to reduced anti-tumor immunity. MDSCs, on the other hand, can promote an immunosuppressive environment by producing factors such as arginase and nitric oxide, which inhibit T cell function [5].

Additionally, some studies have shown that activated T cells can exhibit tumor-promoting properties by producing cytokines that enhance tumor cell proliferation and survival. The balance between pro-inflammatory and anti-inflammatory signals within the TME is critical in determining tumor fate [6].

Despite the challenges of immune evasion, immune cells can also exert strong anti-tumor effects. Cytotoxic T cells play a central role in recognizing and killing tumor cells that present abnormal antigens (Schreiber et al., 2011). Moreover, DCs are crucial for priming naive T cells and shaping the adaptive immune response against tumors. Their ability to present tumor antigens and produce pro-inflammatory cytokines can enhance T cell activation and recruitment to the TME [7].

Understanding the complex interactions between immune cells and the TME has significant implications for cancer therapy. Here are several potential strategies: Therapies targeting immune checkpoints, such as PD-1 and CTLA-4, have shown remarkable success in reactivating anti-tumor immune responses. By blocking these inhibitory pathways, these therapies aim to restore T cell function and promote tumor rejection [8].

Strategies to reprogram TAMs from an M2 to an M1 phenotype are being explored. This includes using agents that inhibit M2-associated signaling pathways or promoting the recruitment of M1 macrophages to the TME. DC vaccines and therapies aimed at enhancing the function of dendritic cells are under investigation. By improving their ability to present tumor antigens and activate T cells, these approaches aim to boost the adaptive immune response against cancer [9].

Immune cells in the TME can also promote tumor growth. For instance, TAMs often adopt an M2 phenotype in the presence of tumor-derived signals, leading to the secretion of pro-tumorigenic factors such as IL-10 and TGF-β. This macrophage polarization not only supports tumor growth but also facilitates angiogenesis and metastasis [10].

Conclusion

The tumor microenvironment is a dynamic and complex ecosystem where immune cells play a critical role in cancer progression. The interplay between immune cells and tumor cells can either promote or inhibit tumor growth, highlighting the duality of immune responses in cancer. A deeper understanding of these interactions can inform the development of novel therapeutic strategies aimed at harnessing the immune system to combat cancer effectively. Continued research into the TME and its immune components holds great promise for improving cancer treatment outcomes.

References

  1. Grizzi G, Caccese M, Gkountakos A, et al., Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. Expert Rev Mol Diagn. 2017;17(12):1055-69.

    2. Indexed at, Google Scholar, Cross Ref

  2. Kreiter S, Vormehr M, Van de Roemer N, et al., Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nat. 2015;520(7549):692-6.

    3. Indexed at, Google Scholar

  3. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nat. 2011;480(7378):480-9.

    4. Indexed at, Google Scholar

  4. Rizvi NA, Hellmann MD, Snyder A, et al., Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Sci. 2015;348(6230):124-8.

    5. Google Scholar

  5. Sahin U, Derhovanessian E, Miller M, et al.,  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nat. 2017;547(7662):222-6.

    6. Google Scholar

  6. Mahmoud F, Shields B, Makhoul I, et al., Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer Biol  Ther. 2017;18(7):451-69.

    7. Indexed at,  Google Scholar

  7. Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Díaz R, et al., Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy. Mol Cancer. 2023;22(1):142.

    8. Indexed at, Google Scholar, Cross Ref

  8. Fernando K, Kwang LG, Lim JT, Fong EL. Hydrogels to engineer tumor microenvironments in vitro. Biomat Sci. 2021;9(7):2362-83.

    9. Indexed at, Google Scholar, Cross Ref

  9. Kantoff PW, Higano CS, Shore ND, et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Eng J Med. 2010;363(5):411-22.

    10. Indexed at, Google Scholar

  10. Maude SL, Laetsch TW, Buechner J, et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Eng J Med. 2018;378(5):439-48.

    11. Indexed at, Google Scholar

Get the App